Ann: HER-Vaxx induced antibodies correlated with tumour reduction, page-81

I have read in the past about disappointment that there hasnt been a deal yet for HER Vaxx. I understand there are lots of different cancer types and subsequently lots of different treatments are required to target specific features of these different cancers. IMU has a pipeline of drugs, are they complimentary or are they likely to overlap in the cancers they can treat? Could this be a factor in no one yet offering a good deal for HER Vaxx? I vaguely recall someone making the comment CF33 might be all that is needed for a wide range of solid tumours.